Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence
Abstract Background Regular factor XIII (FXIII) prophylaxis is standard treatment for congenital FXIII A‐subunit deficiency (FXIII‐A CD). Recombinant factor XIII‐A2 (rFXIII‐A2) was extensively evaluated in the mentor trials. Objective To assess real‐world safety and treatment effectiveness of rFXIII...
Main Authors: | Lone Hvitfeldt Poulsen, Bryce A. Kerlin, Giancarlo Castaman, Angelo Claudio Molinari, Marzia Menegatti, Diane Nugent, Sohan Dey, May‐Lill Garly, Manuel Carcao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-02-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | https://doi.org/10.1002/rth2.12628 |
Similar Items
-
Measuring Factor XIII Inhibitors in Patients with Factor XIII Deficiency: A Case Report and Systematic Review of Current Practices in Japan
by: Shiho Amano, et al.
Published: (2022-03-01) -
Role of blood coagulation factor XIII in vascular diseases
by: Swiss Medical Weekly
Published: (2001-01-01) -
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma
by: Vincenzo Sammartano, et al.
Published: (2023-03-01) -
Research progress of cellular coagulation factor ⅩⅢ
by: XUE Yu-jia, LI Zi-jian
Published: (2021-11-01) -
Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners
by: Bojun Li, et al.
Published: (2022-07-01)